ArticleAIDS and behavior2015
Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.
Article in AIDS and behavior, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?AIDS and behavior · 2016Trial
- Sharing of Investigational Drug Among Participants in the Voice Trial.AIDS and behavior · 2016Trial
- Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.Journal of the International AIDS Society · 2016Trial
- Trial
- Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers.AIDS and behavior · 2021Article
- BIOMEDICAL PREVENTION OF HIV IN WOMEN: CHALLENGES AND APPROACHES, WITH PARTICULAR REFERENCE TO THE VAGINAL MICROBIOME.Transactions of the American Clinical and Climatological Association · 2018Article
- Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women.Journal of AIDS & clinical research · 2017Article
- Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.AIDS and behavior · 2017Article
- Use of Pharmacokinetic Data in Novel Analyses to Determine the Effect of Topical Microbicides as Preexposure Prophylaxis Against HIV Infection.The Journal of infectious diseases · 2016Article
- Disclosure of pharmacokinetic drug results to understand nonadherence.AIDS (London, England) · 2015Article
- Adherence and the Lie in a HIV Prevention Clinical Trial.Medical anthropologyArticle
- Challenges and Opportunities for Preexposure Prophylaxis.Topics in antiviral medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
The VOICE Adherence Strengthening Program (VASP) was implemented in May 2011 to improve adherence counseling in VOICE (MTN-003), a multisite placebo-controlled trial of daily oral or vaginal tenofovir-based Pre-Exposure Prophylaxis (PrEP). Anonymous baseline (N = 82) and final follow-up (N = 75) surveys were administered to counselors and pharmacists at 15 VOICE sites, and baseline (N = 18) and final (N = 26) qualitative in-depth interviews were conducted with purposively selected counseling staff at 13 VOICE sites. Qualitative interviews with VOICE participants (N = 38) were also analyzed for segments related to counseling. Behavioral and biological measures of product use collected in the 6 months prior to VASP implementation were compared to those collected during the 6 months following implementation. Results show that the majority of staff preferred VASP and thought that participants preferred VASP over the previous education and counseling strategy, although there was no evidence to suggest that participants noticed modifications in the counseling approach. No meaningful changes were observed in pre/post levels of reported use or drug detection. Interpretation of results is complicated by mid-trial implementation of VASP and its proximity to early closure of oral and vaginal tenofovir study arms because of futility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.